Annual Report 2019

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2019 119 The United Laboratories International Holdings Limited Annual Report 2019 25. TRADE AND BILLS RECEIVABLES, OTHER RECEIVABLES, DEPOSITS AND PREPAYMENTS (Continued) The following is an analysis of trade receivables by age, net of allowance for credit losses, presented based on dates of goods receipt, which is the same as revenue recognition date, and an analysis of bills receivables by age, net of allowance for credit losses, presented based on the bills issuance date, at the end of the reporting period: 2019 2018 RMB’000 RMB’000 Trade receivables 0 to 30 days 697,533 392,207 31 to 60 days 306,184 460,665 61 to 90 days 127,859 176,782 91 to 120 days 67,030 46,778 121 to 180 days 19,763 32,799 1,218,369 1,109,231 Bills receivables 0 to 30 days 345,572 427,028 31 to 60 days 188,439 316,823 61 to 90 days 216,072 325,024 91 to 120 days 209,528 302,806 121 to 180 days 363,268 460,105 Over 180 days 32,105 23,102 1,354,984 1,854,888 As at 31 December 2019, total bills received amounting to RMB1,354,984,000 (2018: RMB1,854,888,000) and certain bills were further discounted or endorsed by the Group with full recourse. The Group continues to recognise their full carrying amounts at the end of the reporting period and details are disclosed below. All bills received by the Group are with a maturity period of less than one year. As at 31 December 2019, included in the Group’s trade receivables balance are debtors with aggregate carrying amount of RMB214,652,000 (2018: RMB256,359,000) which are past due as at the reporting date. Out of the past due balances, nil (2018: RMB7,845,000) has been past due 90 days or more and is not considered in defaults as the balances were related to customers with sound repayment history and no recent history of default. The Group does not hold any collateral over these balances. Details of impairment assessment of trade and other receivables as at 31 December 2019 and 2018 are set out in Note 41.